Bellicum Pharma: Shares up on positive trial results

Bellicum Pharmaceuticals

08/07/2019 14:27

** Drug developer's shares  BLCM.O  rise 7.4% to $1.38
premarket     
    ** Co reports results from a pediatric trial testing
rivo-cel, its treatment designed to reduce the rate of relapse
of leukemia following stem cell transplant  urn:newsml:reuters.com:*:nGNX51YcdB
    ** Data from the trial will form the basis of co's expected
application for European marketing approval 
    ** Results indicate adding rivo-cel to stem cell transplants
in patients lacking a matched donor delivered comparable
outcomes to HLA-matched unrelated donor transplants, co says
    ** Co says data suggest that, if approved, rivo-cel could
become an attractive treatment option for 20-25% of stem cell
transplant patients who lack an HLA-matched donor
    ** Co is seeking a strategic partner for rivo-cel in
anticipation of its potential commercial launch
    ** Up to Friday's close, stock had fallen 78.4% over the
past year

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))